Cite
HARVARD Citation
Moretto, R. et al. (2021). Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. European journal of cancer. pp. 16-26. [Online].